Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition

被引:50
作者
Fernandez de Larrea, Carlos
Teresa Cibeira, Maria
Elena, Montserrat [2 ]
Ignacio Arostegui, Juan [3 ]
Rosino, Laura
Rovira, Montserrat
Filella, Xavier [2 ]
Yaguee, Jordi [3 ]
Blade, Joan [1 ]
机构
[1] Hosp Clin Barcelona, Serv Hematol, Dept Hematol, E-08036 Barcelona, Spain
[2] Hosp Clin Barcelona, Dept Biochem, E-08036 Barcelona, Spain
[3] Hosp Clin Barcelona, Dept Immunol, E-08036 Barcelona, Spain
关键词
PLUS THALIDOMIDE; ELDERLY-PATIENTS; PREDNISONE; MELPHALAN; BORTEZOMIB; THERAPY; DEXAMETHASONE;
D O I
10.1182/blood-2009-06-224832
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of an abnormal serum free light chain (FLC) ratio in 34 patients with multiple myeloma in complete response (CR) after hematopoietic stem cell transplantation was studied. Fourteen of 34 patients (41.2%) showed an abnormal FLC ratio. The frequency of abnormal FLC ratio in patients with or without oligoclonal bands was 72.7% versus 26%, respectively (P = .023). The median value of FLC ratio was 2.55 (95% confidence interval, 1.89-3.20) in patients with oligoclonal bands versus 0.87 (95% confidence interval, 0.70-1.04) for those with no oligoclonal bands (P = .011). This is the first report showing that the presence of oligoclonal bands in patients with multiple myeloma in CR frequently results in an abnormal FLC ratio. Because an oligoclonal immune response is associated with a good outcome, our results question the current definition of stringent CR and support that the prognostic impact of oligoclonal bands should be also assessed on multivariate analysis. (Blood. 2009; 114: 4954-4956)
引用
收藏
页码:4954 / 4956
页数:3
相关论文
共 18 条
[1]  
Allen S, 2008, BLOOD, V112, P941
[2]  
[Anonymous], BLOOD
[3]  
Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
[4]  
Cavo M., 2008, BLOOD, V112
[5]  
*COMM CHRON LEUK M, 1968, CANC CHEMOTHER REP, V1, P1
[6]   International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders [J].
Dispenzieri, A. ;
Kyle, R. ;
Merlini, G. ;
Miguel, J. S. ;
Ludwig, H. ;
Hajek, R. ;
Palumbo, A. ;
Jagannath, S. ;
Blade, J. ;
Lonial, S. ;
Dimopoulos, M. ;
Comenzo, R. ;
Einsele, H. ;
Barlogie, B. ;
Anderson, K. ;
Gertz, M. ;
Harousseau, J. L. ;
Attal, M. ;
Tosi, P. ;
Sonneveld, P. ;
Boccadoro, M. ;
Morgan, G. ;
Richardson, P. ;
Sezer, O. ;
Mateos, M. V. ;
Cavo, M. ;
Joshua, D. ;
Turesson, I. ;
Chen, W. ;
Shimizu, K. ;
Powles, R. ;
Rajkumar, S. V. ;
Durie, B. G. M. .
LEUKEMIA, 2009, 23 (02) :215-224
[7]   International uniform response criteria for multiple myeloma [J].
Durie, B. G. M. ;
Harousseau, J-L ;
Miguel, J. S. ;
Blade, J. ;
Barlogie, B. ;
Anderson, K. ;
Gertz, M. ;
Dimopoulos, M. ;
Westin, J. ;
Sonneveld, P. ;
Ludwig, H. ;
Gahrton, G. ;
Beksac, M. ;
Crowley, J. ;
Belch, A. ;
Boccadaro, M. ;
Turesson, I. ;
Joshua, D. ;
Vesole, D. ;
Kyle, R. ;
Alexanian, R. ;
Tricot, G. ;
Attal, M. ;
Merlini, G. ;
Powles, R. ;
Richardson, P. ;
Shimizu, K. ;
Tosi, P. ;
Morgan, G. ;
Rajkumar, S. V. .
LEUKEMIA, 2006, 20 (09) :1467-1473
[8]   Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial [J].
Facon, Thierry ;
Mary, Jean Yves ;
Hulin, Cyrille ;
Benbouker, Lofti ;
Attal, Michel ;
Pegourie, Brigitte ;
Renaud, Marc ;
Guillerm, Jean Luc Harousseau Gaelle ;
Ahletaix, Carine ;
Dib, Mamoun ;
Voillat, Laurent ;
Maisonneuve, Herve ;
Troncy, Jacques ;
Dervaux, Weronique ;
Monconduit, Mathieu ;
Martin, Claude ;
Casassus, Philippe ;
Jaubert, Jerome ;
Jardel, Henry ;
Doyen, Chantal ;
Kolb, Brigitte ;
Anglaret, Bruno ;
Grosbois, Bernard ;
Yakoub-Agha, Ibrahim ;
Mathiot, Claire ;
Avet-Loiseau, Herve .
LANCET, 2007, 370 (9594) :1209-1218
[9]  
HAROUSSEAU JL, 2005, J CLIN ONCOL S15, V26
[10]  
Kumar S., 2008, BLOOD, V112